Commercial Gene Editing Licenses with Freedom to Operate
Solving CRISPR’s biggest problems: freedom to operate and know-how transfer
Based on market feedback, the most important challenge companies face when adopting CRISPR technology for commercial use is the complex landscape of intellectual property (IP). Multiple ownership of Cas9 patents has created uncertainty regarding freedom to operate (FTO).
Demeetra’s Cas-CLOVER technology differentiates from CRISPR/Cas9 because it uses the dimeric Clo051 nuclease, which is as simple and efficient as Cas9 but cleaner with significantly less off-targets. While Cas9 is covered by thousands of patents, Clo051 has a few issued patents, all owned or exclusively licensed by Demeetra.
Watch Our Presentation at BioProcess International
For clients who wish to access foundational CRISPR/Cas9 IP, Demeetra has combined its own Cas-CLOVER IP with the CVC, key foundational CRISPR inventors. This integration of intellectual property provides the most robust freedom-to-operate in the field of CRISPR technology.
Demeetra also operates a 15,000 sq ft laboratory in Lexington, KY equipped to supply high quality reagents and enhance technical applications. Leveraging our extensive experience validated by hundreds of successful gene editing projects in cells, microbes, and plants; we provide clients with the highest quality technical support from the scientists who work with Cas-CLOVER daily.
Evaluation
- 6-to-12-month period
- Evaluation fee includes the cost of reagents
- Expert tech support and optimized protocols
Full Use License
- Best FTO in CRISPR
- Accessible commercial applications, one-time fee options and no royalties
- Own the application IP you develop